Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 30Thoracic 8Gastrointestinal 7NET 6Head & Neck 6Genitourinary 6CNS 6Breast 5Sarcoma 4Gynecologic 4Dermatologic 4Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Other solid neoplasm 1Other 1Myeloid 1

Conditions

Obesity 298Mucositis 116Neoplasms 108Breast Neoplasms 87Overweight 80Sexual Dysfunction, Physiological 74Polycystic Ovary Syndrome 71Dyspnea 48Motor Activity 46Constipation 45Head and Neck Neoplasms 42Weight Loss 36Prostatic Neoplasms 32Pain 29Stomatitis 26Endometrial Neoplasms 23Opioid-Induced Constipation 21Multiple Endocrine Neoplasia Type 1 20Diabetes Mellitus 20Lung Neoplasms 18Colorectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Sexual Dysfunctions, Psychological 15Depression 15Cardiovascular Diseases 15Anxiety Disorders 15Sedentary Behavior 13Insulin Resistance 13Infertility 13Cancer-related Fatigue 13

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrinoma × Other × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡